Systemic lupus erythematosus and thyroid disease: A 10-year study  by Lin, Wen-Ya et al.
Journal of Microbiology, Immunology and Infection (2015) 48, 676e683Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLESystemic lupus erythematosus and thyroid
disease: A 10-year study
Wen-Ya Lin a, Chia-Li Chang d, Lin-Shien Fu a,b,c,*,
Ching-Heng Lin d,**, Heng-Kuei Lin aa Department of Pediatrics, Taichung Veterans General Hospital, Taichung, Taiwan
b Department of Pediatrics, National Yang-Ming University, Taipei, Taiwan
c Institute of Technology, National Jee-Nan University, Nanto, Taiwan
d Department of Medical Research, Taichung Veterans General Hospital, Taichung, TaiwanReceived 3 September 2013; received in revised form 17 December 2013; accepted 19 March 2014
Available online 26 May 2014KEYWORDS
Autoimmune
thyroiditis;
Hyperthyroidism;
Overlap syndrome;
Systemic lupus
erythematosus* Corresponding author. Division of I
160, Chung-Kang Road, Section 3, Tai
** Corresponding author. Department
Taichung City 40705, Taiwan.
E-mail addresses: lsfu@vghtc.gov.t
http://dx.doi.org/10.1016/j.jmii.2014
1684-1182/Copyright ª 2014, TaiwanBackground: This large-scale study aims to analyze the association of systemic lupus erythema-
tosus (SLE) with thyroid diseases.
Methods: In this retrospective, nationwide cohort study, 1633 newly diagnosed SLE patients
from the National Health Insurance Research Database in 2000 were examined and data on pa-
tients with diagnoses of hyperthyroidism, hypothyroidism, and autoimmune thyroiditis were
collected from 2000 to 2009. We subdivided these SLE patients by the presence of overlap syn-
drome. Comparison with 6532 age- and sex-matched controls was performed.
Results: The cumulative incidence of thyroid disease in SLE patients was lower than in controls
(8.1% vs. 16.9%, p < 0.001). Among SLE patients, 39.7% had overlap syndrome. The overlap syn-
drome group had a higher cumulative incidence of thyroid diseases (10.96% vs. 4.57%,
p < 0.0001), hypothyroidism (3.86% vs. 1.93%, p Z 0.017), and autoimmune thyroiditis
(4.63% vs. 0.71%, p < 0.0001) than SLE patients without overlap syndrome. Comparing the data
with the non-SLE-matched control group by logistic regression model revealed a decreased risk
of thyroid diseases with odds ratios (ORs) of 0.25 and 0.62 [95% confidence interval (CI) 0.18
e0.33, 0.48e0.80], and hyperthyroidism with ORs of 0.21 and 0.30 (95% CI 0.14e0.31, 0.20
e0.45) in SLE patients without and with overlap syndrome. SLE patients without overlap syn-
drome had a lower risk of hypothyroidism with an OR of 0.53 (95% CI 0.53e0.86) and autoim-
mune thyroiditis with an OR of 0.26 (95% CI 0.12e0.56). SLE patients with overlap syndrome
showed a similar risk of hypothyroidism with an OR of 0.92 (95% CI 0.66e1.53) and a higher risk
of autoimmune thyroiditis with OR of 1.69 (95% CI 1.14e2.51).mmunology and Nephrology, Department of Pediatrics, Taichung Veterans General Hospital, Number
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Systemic lupus erythematosus and thyroid disease 677Conclusion: SLE patients had a significantly lower rate of thyroid diseases and hyperthyroidism
than matched controls. Among SLE patients, risks of hypothyroidism and autoimmune thyroid-
itis were different in the presence of overlap syndrome. This finding is novel and important for
clinical practices.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Systemic lupus erythematosus (SLE) is a multisystem auto-
immune disease characterized by the production of auto-
antibodies and chronic inflammation of numerous organs
and tissues, including the thyroid gland.1e6 Prevalence of
SLE varies according to age, sex, and geographical differ-
ences of the studied population, with reported prevalence
rates ranging from 12.5 to 50.8/100,000 persons.1 One
important aspect of SLE morbidity is organ damage and the
association of SLE with thyroid disease has been reported
by several studies with a wide range of variability.3e12 Most
papers concord that thyroid disease appears to be more
frequent in SLE patients than in the general population, but
contradictory results exist as to whether hyperthyroidism or
hypothyroidism is more commonly associated.3 Even among
studies regarding SLE-associated hypothyroidism, a wide
range of variability from 4% to 21% has been documented.4
One of the reasons for such variability could be due to the
smaller sample group studied. Thus, this large-scale study
aims to evaluate the prevalence of hyperthyroidism, hy-
pothyroidism, and autoimmune thyroiditis among SLE pa-
tients in Taiwan.
Materials and methods
This study was based on data released from the National
Health Insurance Research Database (NHIRD) in Taiwan. The
National Health Insurance program was started in 1995 with
the aim of providing health-care finance for all residents;
currently, there are more than 25 million enrollees in the
program, representing approximately 99% of Taiwan’s entire
population. The NHIRD provides a wide range of information,
including ambulatory care and inpatient care files, as well as
registration records, including the demographic data of the
insured. The diagnostic code in the database is based on the
system used by the International Classification of Diseases,
9th Revision, Clinical Modifications (ICD-9-CM). For privacy
protection, the identities of the patients, physicians, and
institutions were scrambled in accordance with the Personal
Electronic Data Protection Law.
Data on enrollees with SLE (ICD-9 710.0) were obtained
from the Registry of Catastrophic Illness Database, which is
a subdivision of the NHIRD. These enrollees have all
received a catastrophic illness certificate that grants
exemption from co-payment. The certificate is provided
only after thorough examination of medical records, labo-
ratory and image studies by at least two specialists and only
for those who meet the criteria of these diseases.
Data on enrollees with hyperthyroidism (ICD-9 code
242.9), hypothyroidism (ICD-9 code 244.8, 244.9),thyroiditis, subacute and chronic (ICD-9 code 245.1, 245.2,
245.3, 245.8, 245.9), and autoimmune thyroiditis (ICD code
245.2), scleroderma (ICD-9 code 710.1), Sjo¨gren’s syndrome
(SS; ICD-9 code 710.2), dermatomyositis (ICD-9 code 710.3),
polymyositis (ICD-9 code 710.4), and rheumatoid arthritis
(RA; ICD-9 code 714) were obtained from the NHIRD. Pa-
tients identified were required to have at least one primary
or secondary diagnosis of these diseases in at least one
hospital admission or three outpatient department visits.
Among those identified with thyroid diseases, further sub-
divisions were classified according to treatments received.
Treatment code used were those for thyroidectomy (ICD-9
code 06.3x, 06.4x, 06.5x, 06.6x); I-131 ablation therapy
(NHIRD treatment code 26038A, 26038B); antithyroid
medication including carbimazole and propylthiouracil
(NHIRD drug code A005290100, A017504100, A026328100,
A0263281G0, A033933100, B013004100, A043335100,
A0433351G0, N007870100); and thyroxin supplements
(NHIRD drug code A036236100, AC48191100, AC481911G0,
B024708100).
We recruited 1633 patients newly diagnosed as SLE in
2000, and followed their data up to the end of 2009. The
6532 controls who were matched by age and sex were
sampled.
The number and percentage of age group and sex were
determined for both SLE patients and controls. The preva-
lence and incidence of hyperthyroidism, hypothyroidism,
thyroiditis (subacute and chronic), and chronic lymphocytic
thyroiditis were also calculated. In addition, the Chi-square
test was used to compare the difference of those diseases
between SLE patients and controls. In SLE patients, overlap
syndrome was also described by percentage. The odds ratio
(OR) and 95% confidence interval (CI) were used to estimate
the risk of thyroid diseases in SLE patients with or without
overlap syndrome by comparing the data with controls by
logistic regression models. Data retrieval and analysis were
performed using SAS version 9.3 (SAS Institute Inc., NC,
USA) and the significance level was set at 0.05.Results
The sex and age distribution of the 1633 newly diagnosed
SLE patients and 6532 matched control are shown in
Table 1. The majority of SLE patients were female (89.7%)
and the total female-to-male ratio was 8:1 (Table 1). In
addition, more than half of the newly diagnosed SLE pa-
tients were between 20 and 39 years of age.
Prevalence and incidence of hyperthyroidism, hypothy-
roidism, thyroiditis, and autoimmune thyroiditis among the
SLE and control groups are also tabulated in Table 1. The
prevalence of these thyroid diseases revealed no difference
678 W.-Y. Lin et al.between the SLE and control groups in 2000. During the 10
years of follow-up, the total case number of hyperthy-
roidism in the 1633 SLE patients was 52 (3.2%) compared
with 10.9% in the control group (p < 0.0001); 51.9% of these
required treatment such as thyroidectomy, I-131 ablation,
and antithyroid medicine (p < 0.0001). Hypothyroidism in
the SLE patients accounted for 2.7%, and it was 3.5% in the
control group (p Z 0.115). The majority (97.7%) of these
patients received thyroxin replacement therapy. The cu-
mulative incidence of thyroiditis (subacute and chronic)
was 2.3% and 2.5% in the SLE and control groups, respec-
tively (pZ 0.545); autoimmune thyroiditis was 2% and 1.5%
in these two groups (pZ 0.66). From Table 1, it can be seen
that there are no differences in the prevalence or incidenceTable 1 Comparison of hyperthyroidism, hypothyroidism, th
thyroiditis among SLE patients and the general population from 2
Variable SLE
(n Z 1
n
Age at entry, y
Mean  SD 34.9  14.8
<10 13
10e19 231
20e29 454
30e39 407
40e49 276
50e59 127
60e69 93
70 32
Sex
Female 1464
Male 169
Hyperthyroidism (242.9)
Prevalence case (2000) 29
Incidence case (2000) 19
Incidence case (2000e2009) 52
Incidence case (2001e2009) 33
Case number with treatment (2000e2009) 27
Hypothyroidism (244.8, 244.9)
Prevalence case (2000) 19
Incidence case (2000) 9
Incidence case (2000e2009) 44
Incidence case (2001e2009) 35
Case number with treatment (2000e2009) 43
Thyroiditis (subacute and chronic) (245.1, 245.2, 245.3, 245.8, 2
Prevalence case (2000) 13
Incidence case (2000) 8
Incidence case (2000e2009) 38
Incidence case (2001e2009) 30
Case number with treatment (2000e2009) 0
Chronic lymphocytic thyroiditis (245.2)
Prevalence case (2000) 11
Incidence case (2000) 7
Incidence case (2000e2009) 32
Incidence case (2001e2009) 24
Case number with treatment (2000e2009) 0
SLE Z systemic lupus erythematosus; SD Z standard deviation.of hypothyroidism, thyroiditis (subacute and chronic), or
autoimmune thyroiditis in 2000 and in the subsequent 9
years between the SLE and control groups. There was also
no difference in the prevalence or incidence of hyperthy-
roidism in 2000. However, the control group had much
higher cumulative incidence of hyperthyroidism from 2001
to 2009 than the SLE group (p < 0.00001).
In the SLE group, coexistence of these three thyroid
diseases was noted, as shown in Fig. 1. Coexisting
thyroiditis was found in 15.9% of patients in the SLE group
with hypothyroidism; and in 9.6% of patients in the SLE
group with hyperthyroidism. Eight patients had both hy-
perthyroidism and hypothyroidism, which was due to hy-
perthyroidism therapy.yroiditis (subacute and chronic), and chronic lymphocytic
000 to 2009
Non-SLE p for c2 test
633) (n Z 6532)
(%) n (%)
35.2  15.0 0.493
0.8 52 0.8 1.000
14.2 924 14.2
27.8 1816 27.8
24.9 1628 24.9
16.9 1104 16.9
7.8 508 7.8
5.7 372 5.7
2.0 128 2.0
89.7 5856 89.7 1.000
10.4 676 10.4
1.8 162 2.5 0.092
1.2 75 1.2 0.959
3.2 710 10.9 <0.0001
2.0 635 9.7 <0.0001
1.7 540 8.3 <0.0001
1.2 50 0.8 0.116
0.6 29 0.4 0.569
2.7 227 3.5 0.115
2.1 198 3.0 0.054
2.6 197 3.0 0.413
45.9)
0.8 33 0.5 0.160
0.5 17 0.3 0.133
2.3 165 2.5 0.545
1.8 148 2.3 0.224
0.0 20 0.3 0.0252
0.7 23 0.4 0.071
0.4 14 0.2 0.126
2.0 140 2.1 0.644
1.5 100 1.5 0.856
0.0 4 0.1 0.317
Figure 1. Number of coexistent thyroid diseases among
systemic lupus erythematosus (SLE) patients.
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Systemic lupus erythematosus and thyroid disease 679A total of 648 (39.7%) SLE patients fulfilled the diagnosis
criteria of overlap syndrome in this database. The most
commonly associated diagnoses were SS (n Z 449), fol-
lowed by RA (n Z 240), scleroderma (n Z 75), dermato-
myositis (nZ 29), and polymyositis (nZ 25). We found that
137 patients had two diagnoses of autoimmune diseases
besides SLE; 15 patients had three diagnoses; and one pa-
tient had four diagnoses. The cumulative incidence of
thyroid diseases in SLE patients with overlap syndrome is
shown in Table 2. There were 244 SLE patients younger than
the age of 20. Among them, 78 (32%) had overlap syndrome,
and SS (n Z 53) was also the most common association,
followed by RA (n Z 27). These were similar to the SLE
adult group. However, the rates of thyroid disease (total),
hyperthyroidism, hypothyroidism, thyroiditis (subacute and
chronic), and autoimmune thyroiditis were 8.97%, 3.85%,
2.56%, 2.56%, and 1.28% respectively, which were lower
than in the SLE adult group.
The comparison of cumulative incidence of thyroid dis-
ease, hyperthyroidism, hypothyroidism, and autoimmune
thyroiditis from 2000 to 2009 in the control group, SLE
group with and without overlap syndrome is summarized in
Fig. 2. Both subgroups of SLE had lower rates of thyroid
diseases than the control group; the SLE without overlap
syndrome subgroup showed an even lower rate of thyroid
diseases than the SLE with overlap syndrome subgroup.
Both subgroups had lower rate of hyperthyroidism and
there was no difference of cumulative incidence between
these two subgroups. The subgroup of SLE without overlap
syndrome had a lower rate of hypothyroidism than the
subgroup of SLE with overlap syndrome and the control
group. In terms of thyroiditis (subacute and chronic) and
autoimmune thyroiditis, the subgroup of SLE with overlap
syndrome showed significantly higher rate than the control
group; by contrast, the subgroup of SLE without overlap
syndrome had a lower rate than the control group. Table 3
further calculated the OR for thyroid diseases in these
three groups.
Discussion
Historically, higher rates of thyroid dysfunction and auto-
antibodies have been described in patients with autoim-
mune diseases, including SLE, RA, and SS.13,14 In this
Figure 2. Comparison of total thyroid diseases, hyperthyroidism, hypothyroidism, thyroiditis (subacute and chronic), and chronic
lymphocytic thyroiditis in the control, systemic lupus erythematosus (SLE) nonoverlap syndrome, and SLE overlap syndrome groups.
680 W.-Y. Lin et al.nationwide, cohort study, the overall rate of hyperthy-
roidism in the SLE group was 3.2%, which is comparable
with those found in previous studies,4,7e9 and the rates of
hypothyroidism and autoimmune thyroiditis were lower
than previously reported.3e10 Nevertheless, if we subdivide
SLE patients based on the presence or absence of overlap
syndrome, we can find significantly higher cumulative
incidence of hypothyroidism and autoimmune thyroiditis in
those SLE patients with overlap syndrome. In comparison
with the control group, SLE patients had a lower cumulative
incidence and risk of thyroid diseases and hyperthyroidism,
which is different from previous studies summarized in
Table 4.3e5,7e10 One possible explanation is the much
higher rate of hyperthyroidism in the control group15 (64.4%
of patients with thyroid disease in the control group had
hyperthyroidism). To ascertain the accuracy of these data,
we performed an analysis on thyroid diseases among the
Taiwanese general population and found the data to be
comparable with our control group. Besides, we checked
the treatment of thyroid diseases for additional confirma-
tion. Among the 52 patients with both SLE and hyperthy-
roidism, 51.9% received treatment and 76% of the
hyperthyroidism cases in the control group received treat-
ment. In terms of hypothyroidism, 97.7% of SLE patients
and 87% of the control group received thyroxin
supplements.
A brief review of previous studies revealed high vari-
ability with prevalence of hyperthyroidism ranging from 0%
to 5.8%, hypothyroidism from 3.9% to 17.4%, and autoim-
mune thyroiditis from 14% to 46.7%.3e10 This might be due
to the limited case numbers (45e300 patients), differences
in statistical analysis, and study designs. Most of these were
observational studies performed at various medical cen-
ters, and some had control groups for comparison. Di-
agnoses of thyroid disease were derived mainly from
thyroid serology tests. In the 22-year retrospective study
performed by Pyne and Isenberg, a larger sample group
(n Z 300 patients) was recruited and clinical records and
laboratory data including thyroid serology results were
analyzed. The prevalence of hypothyroidism (5.7%) wasreported to be higher than the general population (1%),
whereas that of hyperthyroidism (1.7%) was not signifi-
cantly different.8 In the Italian study of 213 SLE patients
(with 426 sex- and age-matched control groups), it was
found that 5.9% of studied female SLE patients had clinical
hypothyroidism; OR for subclinical hypothyroidism in fe-
male patients with SLE with respect to controls was 4.5
(95% CI, 2.0e4.4) and as high as 34.7% of patients had
antithyroid antibodies.4 In addition, Mader et al attempted
to correlate thyroid dysfunction (measured by antithyroid
antibodies level) in SLE patients with SLE disease severity as
measured by the SLE disease activity index score. However,
no association was found. In fact, among the different
variables tested in this study, hypothyroidism was the only
significant abnormal finding with increased prevalence
(11.6%) found in SLE patients as compared with 1.9% of the
control group.5 Our study differs by including a much larger
sample size of 1633 SLE patients with 6532 control, and
then we longitudinally checked the cumulative incidence
up to 10 years, demonstrating a lower incidence of thyroid
diseases and hyperthyroidism among SLE patients.
Coexistent thyroid diseases can also occur. It was
interesting to note that among the SLE patients with hy-
pothyroidism, 15.9% had coexisting autoimmune thyroiditis,
and only 9.6% of SLE patients with hyperthyroidism had
coexisting autoimmune thyroiditis. This suggests that in the
course of autoimmune thyroiditis, decreased thyroid func-
tion is more commonly found.
Clustering of multiple autoimmune diseases has been
described.16e18 At one end are organ-specific diseases such
as autoimmune thyroiditis, whereas at the other end are
diseases with systemic involvement such as SLE. Specifically
related to SLE, previous study results have emphasized that
a higher prevalence of polyautoimmunity was found in SLE
patients (41%).16 Our study also revealed a similar trend
with 39.7% of SLE patients having polyautoimmunity. Higher
association between SLE, SS, and autoimmune thyroiditis
was noted in previous studies.16,18,19 Some authors even
considered these three conditions as “chaperones”.19 Pre-
vious studies have shown that SLE patients who develop SS
Table 4 Summary of hyperthyroidism, hypothyroidism and autoimmune thyroiditis diseases in SLE patients from previous studies
Reference (year of
publication)
Number of
SLE patients
Control
group
Stu y method Study period % of hyperthyroidism % of hypothyroidism % of patients with
antithyroid antibody
Kumar et al (2010)3 100 100 Ob rvational 2 y 0 14 30
Antonelli et al (2010)4 213 426 Ob rvational cross sectional d 1.5 (female: p Z 0.01) 5.9 (female: p < 0.001) 34.7 (p < 0.001)
Mader et al (2007)5 77 52 Ob rvational cross sectional d 0 11.6% (p Z 0.048) 23.4
Pyne and Isenberg (2002)8 300 d Re ospective 22 y 1.7 5.7 14
Chan et al (2001)7 69 d Ob rvational cross sectional d 5.8 17.4 23.2
Tsai et al (1993)9 45 d Ob rvational 1 y 2.2 4.4 46.7
Boey et al (1993)10 129 d Ob rvational cross sectional d 0.8 3.9 32.2
SLE Z systemic lupus erythematosus.
Table 3 Logistic regression analysis of SLE predicting tal thyroid disease adjusted for age and sex
Variable N Total thyroid disease Hyperthyroidism Hypothyroidism Thyroiditis
(subacute and chronic)
Chronic lymphocytic
thyroiditis
(n Z 1190) (n Z 820) (n Z 285) (n Z 215) (n Z 172)
OR 95% CI p R 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
Non-SLE 6532 1 d d d 1 d d d 1 d d d 1 d d d 1 d d d
SLE nonoverlap
syndrome
985 0.245 0.181 0.333 <0.0001 0 11 0.143 0.311 <0.0001 0.533 0.332 0.855 0.0091 0.26 0.122 0.556 0.0005 0.38 0.18 0.77 0.007
SLE overlap
syndrome
648 0.617 0.478 0.796 0.0002 0 01 0.2 0.452 <0.0001 1.008 0.662 1.535 0.9708 1.69 1.137 2.511 0.0095 1.74 1.12 2.71 0.014
CI Z confidence interval; OR Z odds ratio; SLE Z systemi lupus erythematosus.
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682 W.-Y. Lin et al.had significantly frequent anti-Ro antibodies20 and that
patients with SLE and anti-Ro antibodies can also develop
autoimmune thyroiditis.20,21 In our study, SS was the most
commonly coexisting autoimmune disease in SLE. Never-
theless, other autoimmune diseases, including RA, showed
comparable cumulative incidence of thyroid diseases The
SLE overlapping with dermatomyositis, polymyositis, or
scleroderma had lower rates than other overlapping syn-
dromes in this aspect; however, the rates were much higher
than in those SLE patients without overlap syndrome.
In the 1st year of SLE diagnoses the following cases were
diagnosed: 36.5% hyperthyroidism, 20.5% hypothyroidism,
and 21.6% autoimmune thyroiditis. The incidence of thyroid
diseases dropped significantly from the 2nd year of SLE
diagnosis, with the average annual incidence rate
decreasing to approximately 3% for all thyroid diseases.
Systemic conditions, whether acute or chronic, were asso-
ciated with a significant decrease in serum concentration of
total triiodothyronine and free triiodothyronine22 and could
result in disturbed thyroid function. This euthyroid sick
syndrome has been described as a functional thyroid dis-
order in nonthyroidal illness23 and has been found in pa-
tients with various medical and surgical conditions
including SLE. This could provide one explanation for
increased thyroid diseases found within the initial period of
SLE diagnoses. Incidence of thyroid diseases might decrease
with SLE treatment; at least, we did not find an increase in
the rate of thyroid disease following SLE treatment.
The strengths of our study are its use of population-
based data that are highly representative of the general
population. However, certain limitations to our findings
should be considered. First, this study was based on diag-
nostic codes released from the NHIRD, and thus, details on
thyroid serological tests, presence of thyroid autoanti-
bodies, or SLE autoantibodies were not available. Second,
the evidence derived from a retrospective cohort study is
generally inferior in statistical quality to that originating
from randomized trials because of the potential biases
related to adjustments for confounding variables. Despite
our meticulous study design and control measures for con-
founding factors, bias resulting from unknown confounders
might have affected our results. However, the data
regarding the diagnoses of SLE, thyroid diseases, and
autoimmune diseases were nonetheless reliable.
In conclusion, this nationwide, cohort study in SLE pa-
tients demonstrated several unique data not published
previously. We found that the hyperthyroidism in SLE pa-
tients was lower than the matched control group (8.1% vs.
16.9%). SLE patients with overlap syndrome carried a higher
risk of hypothyroidism and autoimmune thyroiditis than
those SLE patients without overlap syndrome. We suggest
that the presence of overlap syndrome should be consid-
ered in clinical practice and future studies involving thyroid
disease(s) in SLE patients.Conflicts of interest
All authors have no conflicts of interest to declare. The
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